TRX-103

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameTRX-103

Drug Alias NameTRX-103TRX103

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tregs

Mechanisms of ActionInterleukin-10 stimulants

TargetsInterleukin-10

Therapy Area/IndicationsGraft vs Host DiseaseMyelodysplastic SyndromesUveitis +[12]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesTr1X Inc

China Registration ClassN/A

Develop Information

Active CompaniesTr1X Inc Stanford University

Inactive CompaniesN/A

Active IndicationsGraft vs Host DiseaseMyelodysplastic SyndromesUveitis +[11]

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A